Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.75 USD | +5.42% | -3.31% | +9.38% |
May. 16 | Reneo Pharmaceuticals Insider Bought Shares Worth $639,578, According to a Recent SEC Filing | MT |
May. 13 | Reneo Pharmaceuticals to Merge With OnKure in All-Stock Deal -- Reneo Shares Rise | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 58.49M |
---|---|---|---|---|---|
Net income 2024 * | -22M | Net income 2025 * | -23M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-2.69
x | P/E ratio 2025 * |
-2.54
x | Employees | 8 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.92% |
1 day | +5.42% | ||
1 week | -3.31% | ||
Current month | +4.79% | ||
1 month | -0.57% | ||
3 months | +6.06% | ||
6 months | -74.11% | ||
Current year | +9.38% |
Managers | Title | Age | Since |
---|---|---|---|
Niall O'Donnell
FOU | Founder | 51 | - |
Gregory Flesher
CEO | Chief Executive Officer | 54 | 20-12-08 |
Michael Grey
FOU | Founder | 71 | 14-09-21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Grey
FOU | Founder | 71 | 14-09-21 |
Director/Board Member | 64 | 17-11-30 | |
Paul Hoelscher
BRD | Director/Board Member | 59 | 22-01-19 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.49% | 4 M€ | -5.15% | - | |
0.00% | 34 M€ | +3.87% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 1.75 | +5.42% | 204,823 |
24-05-16 | 1.66 | +3.75% | 243,687 |
24-05-15 | 1.6 | -1.23% | 424,880 |
24-05-14 | 1.62 | +1.89% | 1,459,798 |
24-05-13 | 1.59 | -12.15% | 6,417,681 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.38% | 58.49M | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B | |
-6.26% | 11.42B |
- Stock Market
- Equities
- RPHM Stock